DK3551181T3 - Behandling omfattende oral eller gastrisk indgivelse af edaravone - Google Patents

Behandling omfattende oral eller gastrisk indgivelse af edaravone Download PDF

Info

Publication number
DK3551181T3
DK3551181T3 DK18701303.2T DK18701303T DK3551181T3 DK 3551181 T3 DK3551181 T3 DK 3551181T3 DK 18701303 T DK18701303 T DK 18701303T DK 3551181 T3 DK3551181 T3 DK 3551181T3
Authority
DK
Denmark
Prior art keywords
edaravone
oral
treatment
gastric administration
gastric
Prior art date
Application number
DK18701303.2T
Other languages
English (en)
Inventor
Sytske Hyke Moolenaar
Der Geest Ronald Van
Original Assignee
Treeway Tw001 B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62908293&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3551181(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/EP2017/067005 external-priority patent/WO2018133957A1/en
Application filed by Treeway Tw001 B V filed Critical Treeway Tw001 B V
Application granted granted Critical
Publication of DK3551181T3 publication Critical patent/DK3551181T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41521,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Physiology (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DK18701303.2T 2017-01-17 2018-01-17 Behandling omfattende oral eller gastrisk indgivelse af edaravone DK3551181T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP17151741 2017-01-17
EP17180087 2017-07-06
PCT/EP2017/067005 WO2018133957A1 (en) 2017-01-17 2017-07-06 Medical treatment comprising enteral administration of edaravone
PCT/EP2018/051097 WO2018134243A1 (en) 2017-01-17 2018-01-17 Treatment comprising oral or gastric administration of edaravone

Publications (1)

Publication Number Publication Date
DK3551181T3 true DK3551181T3 (da) 2020-11-30

Family

ID=62908293

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18701303.2T DK3551181T3 (da) 2017-01-17 2018-01-17 Behandling omfattende oral eller gastrisk indgivelse af edaravone

Country Status (14)

Country Link
US (1) US20190328712A1 (da)
EP (2) EP3551181B1 (da)
JP (2) JP7107624B2 (da)
KR (1) KR102550376B1 (da)
AU (1) AU2018209155B2 (da)
BR (1) BR112019014705A2 (da)
CA (1) CA3050037A1 (da)
DK (1) DK3551181T3 (da)
ES (1) ES2850873T3 (da)
IL (1) IL268127B2 (da)
MX (1) MX392901B (da)
PL (1) PL3551181T3 (da)
RU (1) RU2761967C2 (da)
WO (1) WO2018134243A1 (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3551181T3 (pl) * 2017-01-17 2021-05-31 Treeway Tw001 B.V. Leczenie obejmujące doustne lub dożołądkowe podawanie edarawonu
WO2018133957A1 (en) 2017-01-17 2018-07-26 Treeway Tw001 B.V. Medical treatment comprising enteral administration of edaravone
ES3059578T3 (en) * 2017-07-06 2026-03-23 Treeway Tw001 B V Use of edaravone in oral treatment of oxidative-stress mediated neurodegenerative disorders
US11826352B2 (en) 2018-11-02 2023-11-28 Mitsubishi Tanabe Pharma Corporation Edaravone suspension for oral administration
CN112969459B (zh) 2018-11-02 2023-12-05 田边三菱制药株式会社 用于口服给药的依达拉奉混悬剂
US12194025B2 (en) 2020-11-12 2025-01-14 Mitsubishi Tanabe Pharma Corporation Pharmaceutical composition for oral administration of edaravone and method of administering same
CN116761601A (zh) * 2020-11-12 2023-09-15 田边三菱制药株式会社 依达拉奉口服给药用医药组合物及其给药方法
WO2024172852A1 (en) * 2023-02-16 2024-08-22 Slayback Pharma Llc Stable pharmaceutical compositions of edaravone

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002034264A1 (en) 2000-10-24 2002-05-02 Mitsubishi Pharma Corporation Remedies for amyotrophic lateral sclerosis (als)
JP2004002400A (ja) 2002-04-23 2004-01-08 Mitsubishi Pharma Corp 軽微低体温療法を行うために用いる脳保護及び/又は脳機能正常化のための医薬
JP2004091441A (ja) * 2002-09-04 2004-03-25 Mitsubishi Pharma Corp ピラゾロン誘導体を含有する経口投与製剤
CA2555457C (en) * 2004-02-09 2012-08-21 Mitsubishi Pharma Corporation A novel therapeutic agent for amyotrophic lateral sclerosis (als) or diseases caused by als
JP2008280253A (ja) 2007-05-08 2008-11-20 Ohara Yakuhin Kogyo Kk エダラボン注射液
JP2009143902A (ja) 2007-11-21 2009-07-02 Kowa Co エダラボンを含有する安定な水溶性製剤
CN101801195A (zh) * 2007-11-21 2010-08-11 帝国制药美国公司 吡唑啉酮衍生物乳液制剂
JP2009143922A (ja) 2007-11-22 2009-07-02 Fujiyakuhin Co Ltd 注射剤
JP2009155315A (ja) 2007-12-26 2009-07-16 Fujiyakuhin Co Ltd 注射剤
JP2009280561A (ja) 2008-05-26 2009-12-03 Fujiyakuhin Co Ltd 注射剤
JP2010047482A (ja) * 2008-08-19 2010-03-04 Ohara Yakuhin Kogyo Kk エダラボン注射液
JP2010077104A (ja) 2008-08-29 2010-04-08 Nihon Pharmaceutical Co Ltd 3−メチル−1−フェニル−2−ピラゾリン−5−オン注射用水溶液
US9006280B2 (en) * 2008-11-20 2015-04-14 Teikoku Pharma Usa, Inc. Pyrazolone derivative formulations
CN101953832B (zh) 2010-08-10 2012-02-15 南京师范大学 β-环糊精包合依达拉奉的口服药物组合物及其制备方法
CN102349893A (zh) * 2011-08-19 2012-02-15 福建天泉药业股份有限公司 依达拉奉药物组合物
KR20200105980A (ko) 2011-09-05 2020-09-09 미쓰비시 타나베 파마 코퍼레이션 근위축성 측색경화증의 치료 또는 병세 진전 억제를 위한 약제
CN113768879A (zh) 2016-03-16 2021-12-10 苏州澳宗生物科技有限公司 依达拉奉剂型
PL3551181T3 (pl) * 2017-01-17 2021-05-31 Treeway Tw001 B.V. Leczenie obejmujące doustne lub dożołądkowe podawanie edarawonu

Also Published As

Publication number Publication date
JP7107624B2 (ja) 2022-07-27
JP2020506959A (ja) 2020-03-05
RU2019125848A3 (da) 2021-04-12
IL268127B1 (en) 2024-08-01
PL3551181T3 (pl) 2021-05-31
EP3551181B1 (en) 2020-11-18
EP3551181A1 (en) 2019-10-16
AU2018209155A1 (en) 2019-08-01
IL268127B2 (en) 2024-12-01
IL268127A (en) 2019-09-26
AU2018209155B2 (en) 2023-11-30
CA3050037A1 (en) 2018-07-26
EP3785703A1 (en) 2021-03-03
BR112019014705A2 (pt) 2020-02-18
US20190328712A1 (en) 2019-10-31
KR20190111929A (ko) 2019-10-02
RU2761967C2 (ru) 2021-12-14
KR102550376B1 (ko) 2023-07-04
JP7415236B2 (ja) 2024-01-17
JP2022137179A (ja) 2022-09-21
RU2019125848A (ru) 2021-02-19
ES2850873T3 (es) 2021-09-01
WO2018134243A1 (en) 2018-07-26
MX2019008489A (es) 2019-11-11
MX392901B (es) 2025-03-24

Similar Documents

Publication Publication Date Title
DK3551181T3 (da) Behandling omfattende oral eller gastrisk indgivelse af edaravone
EP3612132A4 (en) MANUFACTURING OF DENTAL APPLIANCES
EP3568783A4 (en) MEDICAL ASSISTANT
EP3463228A4 (en) INTRAOCULAR DELIVERY
EP3389490A4 (en) IMU CALIBRATION
DK3244948T3 (da) Bestemmelse af medikamentdosis
LT4331584T (lt) Lanifibranoro deuterintų darinių terapietiniai naudojimai
DK3487505T3 (da) Indgivelse og dosering af diaminophenothiaziner
PL3600374T3 (pl) Leczenie zakażenia układu oddechowego
HUE045906T2 (hu) Új szulfonimidoilpurinon vegyületek és származékok vírusfertõzés kezelésére és megelõzésére
EP3347334A4 (en) DEHYDROHALOGENICATION OF FLUOROCHOLE HYDROGEN
EP3525841A4 (en) MICRO DELIVERY DEVICE
DK3503934T3 (da) Fremgangsmåder til selektiv modificering af medicinske slangers fleksibilitet
HUE059584T2 (hu) Gyógyszerészeti készítmény vérszegénység kezelésére
DK3697418T3 (da) Forbedrede formuleringer af bromocriptin
PL3424499T3 (pl) Kompozycja farmaceutyczna do leczenia bólu neuropatycznego
DK3297619T3 (da) Terapeutiske anvendelser af L-4-chlorkynurenin
DK3570819T3 (da) Medicinsk behandling omfattende enteral indgivelse af edaravone
EP3407974A4 (en) Amlexanox Analogs
DK3307239T3 (da) Formuleringer til indgivelse af RSV- og norovirusantigener i tyndtarmen
DK3403674T3 (da) Farmaceutiske sammensætninger til behandling af smerte
DK3398868T3 (da) Bæger eller kapsel
IL285765A (en) Therapeutic uses of dulaglutide
DE202017101527U8 (de) Selbstkriechender Magen-Darm-Nasenkatheter
DK3416654T3 (da) Medicinsk anvendelse af 5'-adenosindiphosphatribose (adpr)